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We have previously documented that raloxifene enhances the
mechanical properties of dog vertebrae independent of
changes in bone mass, suggesting a positive effect of ralox-
ifene onmaterial-levelmechanical properties. The goal of this
study was to determine the separate effects of raloxifene on
the material-level mechanical properties of trabecular and
cortical bone from the femur of beagle dogs. Skeletallymature
female beagles (n ! 12 per group) were treated daily for 1 yr
with oral doses of vehicle or raloxifene (0.50 mg/kg!d). Tra-
becular bone mechanical properties were measured at the
femoral neck using reduced platen compression, a method
that allows the trabecular bone to be tested without coring
specimens. Cortical bone properties were assessed on pris-
matic beam specimens machined from the femoral diaphysis
using both monotonic and dynamic (cyclic relaxation) four-
point bending tests. Trabecular bone from raloxifene-treated
animals had significantly higher ultimate stress ("130%),
modulus ("89%), and toughness ("152%) compared with ve-
hicle-treated animals. Cortical bone from raloxifene-treated
animalshad significantly greater toughness ("62%) compared
with vehicle, primarily as a function of increased postyield
displacement ("100%). There was no significant difference
between groups in the percentage of stiffness loss during cor-
tical bone cyclic relaxation tests. These results are consistent
with previous data from the vertebrae of these same animals,
showing raloxifene has positive effects on biomechanical
properties independent of changes in bone volume/density.
This may help explain how raloxifene reduces osteoporotic
fractures despite modest changes in bone mass. (Endocrinol-
ogy 148: 3908–3913, 2007)
FRACTURE RISK IS determined in part by the skeleton’sbiomechanical properties, most notably the load car-
rying capacity and the ability to absorb energy (1, 2). These
whole bone properties (ultimate load and energy absorption)
can be improved by increasing bone mass/density, by al-
tering the geometry or architecture of the bone, and/or by
enhancing the material-level mechanical properties of the
bone. We have previously shown, using a beagle dog model,
that raloxifene has beneficial effects on whole bone mechan-
ical properties of lumbar vertebrae independent of changes
in bone density (3). These findings are consistentwith clinical
trials of post menopausal women, in which raloxifene has a
modest effect on vertebral bone density yet significantly re-
duces vertebral fracture risk (4–6). Furthermore, changes in
vertebral BMD with raloxifene have been shown to explain
only 4% of the reduction in vertebral fracture risk (7). These
data suggest raloxifene reduces fracture risk in ways that do
not involve large changes in BMD (8, 9).
As the vertebra is comprised of both trabecular and cortical
bone, our previous studies were not able to address whether
one or both bone types experienced altered material prop-
erties with raloxifene treatment (3). This is an important
distinction, as it could help shed light on the mechanism for
the antifracture efficacy of raloxifene, which is currently un-
clear (9). For instance, if beneficial effects exist predominately
in trabecular bone, it may suggest alterations in trabecular
architecture (10), or reductions in resorption cavity stress
risers (11, 12) may explain enhanced fracture resistance with
raloxifene. Positive changes in biomechanical properties of
both cortical and trabecular bone would suggest raloxifene
has an effect on the bone tissue itself, and that the effect is
likely mediated independently of turnover suppression. It is
well accepted that annual turnover rates of trabecular bone
exceed those of cortical bone (13), making the effect of re-
modeling suppression more prominent at trabecular bone
sites. If the positive effects of raloxifene are linked to remod-
eling suppression, it would be predicted that trabecular, but
not cortical bone would show improved biomechanical
properties.
The goal of this study was to use material-level biome-
chanical tests to separately evaluate the effects of raloxifene
on cortical and trabecular bone. Our hypothesis was that
raloxifene would improve the material properties of trabec-
ular bone while having minimal effect on cortical bone com-
pared with vehicle-treated animals.
Materials and Methods
Experimental design
All procedures were approved before the study by the Indiana Uni-
versity School of Medicine Animal Care and Use Committee. One-year-
old female beagles were randomized into two groups (n ! 12/group)
and treated daily for 1 yr with oral doses of saline vehicle (1 ml/kg!d)
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or raloxifene (0.5 mg/kg!d) as previously described (3). This dose of
raloxifene was chosen to produce serum levels similar to those of the
dose used to treat postmenopausal osteoporosis in humans (data on file;
Eli Lilly Co., Indianapolis, IN). After 1 yr of treatment, bilateral femora
were harvested and stored at "20 C until analyses.
Trabecular bone biomechanical tests: reduced platen
compression (RPC)
Femoral neck specimens were prepared for microcomputed tomog-
raphy (microCT; right femur) or RPC (left femur). This bone site was
chosen because it contained an appreciable amount of trabecular bone
(Fig. 1). Bones were thawed to room temperature, and a 3-mm-thick
specimen was cut perpendicular to the neck axis under constant irri-
gation using a band saw (right femur) or low speed Isomet saw (left
femur), each with a diamond tipped blade.
The right femoral neck specimen was scanned using microCT (!CT-
20; Scanco Medical, Bassersdorf, Switzerland). The scanning location
corresponded to the mid-region of the isolated specimen (2 mm thick-
ness; 119 slices, 17 !m isotropic resolution). Trabecular bone morpho-
metric indices, assessed using three-dimensional image reconstructions,
included trabecular bone volume fraction (BV/TV), trabecular thick-
ness, trabecular number, and trabecular separation.
The left femoral neck was prepared for reduced platen compression
(RPC), as previously described with slight modifications (14). Isolated
specimens (#3 mm thick) were radiographed and digitized to obtain
cross-sectional images (Fig. 1) for platen sizing. Compression platens
were sized to correspond to 70% of the largest circle inscribedwithin the
endocortical perimeter. Platen sizingwas rounded to the nearest 0.1 mm
diameter. Before testing each specimen, a visual inspection of the platen-
bone interface was performed to ensure that the platens were not con-
tacting cortical bone.
Specimens were loaded to failure under displacement control (0.5
mm/min), and data were collected at 10 Hz (Instron 1125; Instron,
Norwood, MA). Trabecular bone apparent material properties were
estimated assuming uniaxial compression of the cylindrical region di-
rectly between the platens. Specifically, ultimate stress ("ult), elastic
modulus (E), and toughness (u) were calculated using the following
equations: "ult ! (F/A), E ! (k $ L/A), and u ! U/(L $ A); where F
is the maximum force, A is the cross-sectional area of the platens, L is
the specimen thickness, k is the slope of the linear portion of the load-
displacement curve, andU is the area under the load-displacement curve
up to ultimate load. Considering only a fraction of the volume between
the two compressive platens is comprised of bone, "ult, E, and u were
further normalized by BV/TV measured on the contralateral femoral
neck.
Cortical bone biomechanical tests
Cortical bone beam specimensweremachined from themiddiaphysis
of the femur. Under constant irrigation, the midportion of the shaft (#30
mm length) was isolated using a band saw, and two prismatic beams
were cut along the longitudinal axis of the anterior and posterior cortices
using a wire saw (Histosaw; Delaware Diamond Knives, Wilmington,
DE). Surfaces were sanded with 400-grit sandpaper until the beam was
in #0.2 mm of the final dimensions, with final polishing done using
600-grit sandpaper to achieve final dimensions of 25 mm (length), 1.8
mm (width), and 1.5 mm (height) for each of the two beams. Anterior
and posterior cortex beams were randomized between monotonic and
relaxation four-point bending tests.
One beam was subjected to monotonic four-point bending under
displacement control (3 mm/min) and data was collected at 10 Hz
(EnduraTEC; Bose, Eden Prairie, MN). Structural properties of strength,
stiffness, displacement, and energy absorption were obtained from the
load/deformation curve. Material properties of "ult, E, and u were
estimated using standard equations "ult ! F $ (3a/wt2), E ! (k/wt3) $
(6La2)" 8a3), u! 9U/(wt(3L" 4a)), where L is the bottom support span
(21 mm), a is the span between the top support (6 mm), t is specimen
thickness, w is specimen width, F is the maximum force, k is the slope
of the linear portion of the load-displacement curve, and U is the area
under the load-displacement curve up to fracture. Yield displacement,
for use in the relaxation test, was calculated using a 0.2-mm offset (15).
The second beam was used for cyclic relaxation tests following a
previously published protocol (16) (Fig. 2). The goal of this test was to
Right FN - µCT Left FN - R PC
FIG. 1. Graphical depiction of femoral neck trabecular bone analyses.
The central portion of the each femoral neck was isolated, with the
right neck undergoing microCT analysis to determine trabecular ar-
chitecture and the left femoral neck undergoing RPC to determine
material properties. The circle inscribed on the radiographed image
of the left femoral neck approximates the region of platen contact
during the RPC test.
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FIG. 2. Top, Schematic of four-point bending test setup for testing of
cortical bone beam specimens. This same testing setup was used for
monotonic compression and relaxation tests.Bottom, Schematic of the
relaxation test protocol used to assess cortical bone properties under
cyclic loading conditions. In this 15-cycle test, specimens undergo an
alternating series of diagnostic (cycles 1, 3, 5, 7, 9, 11, 13, 15) and
damage (cycles 2, 4, 6, 8, 10, 12, 14) cycles. For diagnostic cycles,
specimenswere loaded to 50% of yield displacement (determined from
monotonic tests), held for 1 min, and then unloaded. Damage cycles
were loaded to 50, 75, 100, 125, 150, 175, and 200% of yield displace-
ment, held for 1 min, and then unloaded. After each damage cycle,
specimens were allowed a 5-min rest period. All loading and unload-
ing occurred at a rate of 3 mm/min.
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assess material properties under cyclic loading conditions. This protocol
was chosen, rather than a true fatigue test, due to the relatively short
nature of the relaxation test (#1 h). Using a 15-cycle test, specimens
undergo an alternating series of “diagnostic” and “damage” cycles un-
der four-point bending. For diagnostic cycles (cycles 1, 3, 5, 7, 9, 11, 13,
15), specimens were loaded to 50% of yield displacement (determined
frommonotonic tests), held for 1 min, and then unloaded. Displacement
to 50% yield has been shown to provide adequate evaluation of stiffness
without producing additional damage to the specimen (16). Damage
cycles (cycles 2, 4, 6, 8, 10, 12, 14) were loaded to 50, 75, 100, 125, 150,
175, and 200% of yield displacement, held for 1 min, and then unloaded.
Between each damage cycle, and the subsequent diagnostic cycles, spec-
imens were allowed a 5-min rest period. All loading and unloading
occurred at a rate of 3 mm/min. Specimens were kept moist with
physiological saline solution throughout the test.
Themagnitude of stiffness degradationwas used to evaluate changes
in specimens throughout the test. Stiffness was calculated as the slope
of the linear portion of the load/displacement curve from each of the
diagnostic cycles. Baseline stiffness was determined by the average of
the first diagnostic cycle (cycle 1), the first damage cycle (50% yield
displacement; cycle 2), and the second diagnostic cycle (cycle 3). The
percentage of stiffness loss for each of the damage cycles was calculated
as: (baseline stiffness " new stiffness)/baseline stiffness $ 100.
Statistics
All statistical tests were performed using SAS (SAS Institute, Inc.,
Cary, NC). Data were compared between groups using two-tailed Wil-
coxon-Mann-Whitney (percentage of stiffness loss from relaxation tests)
or Student’s t tests (all other data) with P % 0.05 considered significant.
All data are presented as mean & se.
Results
Two specimens from vehicle-treated animals were dam-
aged during machining, leaving n ! 10 specimens for data
collection. There was no significant difference in femoral
neck trabecular bone volume, or measures of trabecular ar-
chitecture, between vehicle- and raloxifene-treated animals
(Table 1). Despite these similarities, specimens from ralox-
ifene-treated animals had significantly higher ultimate stress
('130%), modulus ('89%), and toughness ('152%) com-
pared with vehicle-treated animals (Fig. 3).
Raloxifene-treatment significantly increased cortical bone
total energy to failure, a structural parameter, comparedwith
vehicle ('61%; P! 0.016) (Fig. 4A). Thematerial level equiv-
alent of energy, toughness, was also significantly higherwith
raloxifene ('62%, P ! 0.014) compared with vehicle treat-
ment (Fig. 4B). These changes were due primarily to a sig-
nificant prolonging of the postyield displacement ('97%;
P ! 0.01) compared with vehicle (Fig. 4D), with no change
in preyield displacement between the two groups (Fig. 4C).
There was no significant difference in any of the other struc-
tural properties between the two groups (Table 1). The two
other material-level properties—ultimate stress ('7%; P !
0.129) andmodulus ('7%;P! 0.152)—were not significantly
altered with raloxifene.
There was no significant difference in the percentage of
stiffness loss between cortical bone specimens from ralox-
ifene- or vehicle-treated animals at any stage of the relaxation
tests (Fig. 5). Stiffness degradation was nonsignificantly
greater with vehicle treatment compared with raloxifene at
yield displacements of 100% ('8%; P ! 0.10), 125% ('7%;
A B C
FIG. 3. Significant alterations of trabecular bone material-level biomechanical properties with raloxifene. After RPC testing, properties of
ultimate stress (A), modulus (B), and toughness (C) were calculated. As only a portion of the region between the two RPC platens contains bone,
values were normalized by BV/TV (assessed on contralateral femoral neck), thereby more accurately estimating the properties of the material.
Raloxifene significantly increased all three parameters, compared with vehicle. Data are presented as mean & SE.
TABLE 1. Properties of femoral neck trabecular bone and femoral
shaft cortical bone
Vehicle Raloxifene P value
Trabecular bone (n) 10 12
BV/TV (%) 33.1 & 1.2 31.3 & 1.7 0.402
Tb.N (1/mm) 3.23 & 0.16 2.99 & 0.15 0.275
Tb.Th (!m) 119 & 3.6 117 & 3.8 0.663
Tb.Sp (!m) 324 & 11.2 334 & 11.0 0.524
Cortical bone (n) 12 12
BMD (g/cm2) 0.121 & 0.001 0.122 & 0.001 0.517
Ultimate load (N) 56.5 & 2.5 60.8 & 0.92 0.124
Yield load (N) 44.4 & 1.5 45.6 & 0.95 0.489
Stiffness (N/mm) 77.3 & 2.7 83.9 & 2.4 0.080
Ultimate stress
(MPa)
238 & 9 254 & 5 0.129
Modulus (GPa) 16.7 & 0.5 17.8 & 0.6 0.152
Tb.Th, Trabecular thickness; Tb.N, trabecular number; Tb.Sp, tra-
becular separation; BMD, bone mineral density; MPa, megapascal;
GPa, gigapascal.
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P! 0.52), 150% ('14%;P! 0.52), and 175% ('11%;P! 0.83).
Raloxifene specimens had nonsignificantly greater stiffness
loss at 200% yield ('20%; P ! 0.31) compared with vehicle.
Discussion
These results show that raloxifene has positive effects on
biomechanical properties of both cortical and trabecular
bone independent of changes in bone volume/density. This
is consistent with results in these same animals at another
bone site (vertebra) (3), as well as results from clinical trials
where raloxifene significantly reduces vertebral fracture risk
despiteminimal changes in bone density (4–6). Although the
material-level benefits of raloxifene are clear, the mechanism
for such changes remains to be determined.
Raloxifene appears to alter the properties of preexisting
bone tissue, as opposed to altering the composition of newly
synthesized matrix. This is best illustrated by the significant
changes in cortical bone properties such as energy to failure
and toughness. Intracortical bone turnover in long bone di-
aphysis of this age beagle is relatively slow (17). Although
this dose of raloxifene (0.50 mg/kg!day) was not found to
significantly suppress intracortical bone turnover of the rib
in these same animals (18), this degree of alteration in tissue
toughness would seem rather large to be accounted for by a
change in such a small percentage of the tissue. Conse-
quently, themost likely scenario is that thematerial property
changes caused by raloxifene treatment are occurring at least
in part within the preexisting bone matrix.
Because there is no significant change in the trabecular
bone volume or cortical bonemineral density after raloxifene
treatment in this study, we hypothesize that raloxifene im-
proves mechanical properties by altering properties of the
organic matrix. Collagen is generally considered to contrib-
ute primarily to the postyield properties of bone (19) includ-
ing such parameters as energy absorption and toughness
(20–22). Analyses of vertebral bone of these same animals
failed to find significant differences in collagen cross-links
(pyridinoline, deoxypyridinoline), advanced glycation end
A B
C D
FIG. 4. Raloxifene alters energy to fail-
ure and toughness of cortical bone
through changes in postyield displace-
ment. Prismatic beams machined from
the femoral diaphysis were subjected to
four-point monotonic bending. Ralox-
ifene significantly increased energy ab-
sorption (A) and toughness (B) compared
with bone from vehicle-treated animals
(A). These changes resulted from signif-
icant increases in postyield displace-
ment (D) with no change in preyield dis-
placement (C). Data are presented as
mean & SE.
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products (pentosidine), or collagen isomerization (ratio of
#/$ C-telopeptide) between vehicle and raloxifene-treated
animals (23). However, there remain several other potential
changes to the collagen matrix that could manifest changes
in biomechanical properties. For example, it is possible that
raloxifene could alter the concentrations of divalent cross-
links (hydroxylysinonorleucine or dihydroxylysinonor-
leucine) or pyrrole cross-links, changes that each could alter
mechanical properties (21, 24). Raloxifene could also affect
the interaction between the organic matrix and mineral crys-
tals, known to influence biomechanical properties (22). Al-
ternatively, these effects could be related to suppression of
osteocyte apoptosis, through reduction of reactive oxygen
species, by raloxifene (25).
The positive effects of raloxifene on material-level biome-
chanical properties were not as evident in the cyclic relax-
ation tests. At displacement levels corresponding to those
achieved during the quasi-static tests (%150% yield displace-
ment), the specimens from raloxifene-treated bones tended
not to lose as much stiffness compared with vehicle. Al-
though these changes were not statistically significant, the
trends are consistent with the results from the quasi-static
tests. It is important to note that although we used this
relaxation test to assess cyclic loading properties of the ma-
terial, the protocol was developed to assess differences in the
propensity of the bone to form, accumulate and/or propa-
gate microdamage (16, 26). Our results suggest that the pro-
pensity to initiate/accumulate damage under cyclic loading
conditions is not significantly altered with raloxifene.
Whether these results are indicative of an absence of alter-
ations in the true fatigue properties of the material with
raloxifene remain unclear.
Clinical trials with raloxifene have not demonstrated sig-
nificant nonvertebral fracture risk reduction in postmeno-
pausal women (5, 6). Use of the femoral neck in the current
study to assess trabecular bone properties was not meant to
address issues of hip fracture efficacy, but rather was chosen
due to its general size and appreciable amount of trabecular
bone. Nevertheless, these results may not be completely in-
consistent with the results of the clinical trials. The Multiple
Outcomes of Raloxifene Evaluation study had only 12%
power to detect a 20% reduction in hip fractures (5, 6). This
power was likely further compromised by the removal of a
greater number of women from the placebo group (com-
paredwith raloxifene) because of rapid bone loss or multiple
vertebral fractures during the study. Finally, in a subset
analysis of thosewomenwith the lowest t scores ("2.5) at the
femoral neck, a significant reduction in nonvertebral frac-
tureswas noted (27).Moreover, thematerial properties of the
bone tissue are just one of many factors in the etiology of a
hip fracture. It is also true that, although we detected a large
and significant improvement in the material properties of
both trabecular and cortical bone in the femur, strength and
stiffness of the whole bone were not assessed.
These data should be considered within the context of
various study limitations. Our study used intact female bea-
gles; therefore the effects of raloxifene in the absence of
estrogen, or in a model with established osteoporosis, could
differ. In addition, we have assessed only one dose of ralox-
ifene (chosen to produce serum levels within the range of
those from postmenopausal women treated with the 60-mg
dose) and, therefore, cannot be assured similar results would
occur at other doses. As the trabecular bone tested during
RPC remains connected to the cortical shell, some degree of
load-sharing occurs during the test. Although this is as-
sumed to be similar between treatment conditions (as bone
volume was not changed), we cannot discount that the con-
tribution of the cortical shell may play some role in differ-
ences in trabecular bone properties of the specimens from the
femoral neck.
In conclusion, we show that raloxifene imparts significant
improvements in the material-level properties of both cor-
tical and trabecular bone. As these changes were found to
occur in both trabecular and cortical bone, they appear to be
independent of turnover suppression and therefore occur in
preexisting bone. The changes in material-level properties
observed with raloxifene are consistent with alterations in
the organic matrix. This may help explain how raloxifene
reduces osteoporotic fractures despite modest changes in
bone mass.
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